Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1976 Aug;58(2):289–297. doi: 10.1172/JCI108471

De novo synthesis of purine nucleotides in human peripheral blood leukocytes. Excessive activity of the pathway in hypoxanthine-guanine phosphoribosyltransferase deficiency.

S Brosh, P Boer, B Kupfer, A de Vries, O Sperling
PMCID: PMC333182  PMID: 956368

Abstract

Human peripheral blood leukocytes were studied for the presence and the regulatory properties of the pathway of de novo synthesis of purine nucleotides. The cells were found to incorporate the labeled precursors formate and glycine into purines. The rate of [14C]-formate incorporation was decreased by several compounds known to inhibit purine synthesis by affecting the activity by glutamine phosphoribosylpyrophosphate (PRPP) amidotransferase, the first committed enzyme in the pathway, either through decreasing the availability of PRPP, a substrate for this enzyme, or through exerting inhibition on this enzyme. PRPP availability in the leukocyte was found to be limiting for purine synthesis. Increased PRPP availability resulting from activation of PRPP synthetase by increasing inorganic phosphate (Pi) concentration caused acceleration of purine synthesis. On the other hand, no clear-cut evidence was obtained for the availability of ribose-5-phosphate in the leukocyte being rate limiting at physiological extracellular Pi concentration for PRPP generation, and thus for purine synthesis. However, the addition of methylene blue, which accelerates the oxidative pentose shunt that produces ribose-5-phosphate, resulted in acceleration of PRPP generation and of purine synthesis only when PRPP synthetase was largely activated at high Pi concentration. These results may be taken to suggest that ribose-5-phosphate availability is indeed not limiting for PRPP generation under physiological conditions. Purine synthesis de novo was accelerated more than 13-fold in the leukocytes of two gouty patients affected with partial deficiency of hypoxanthine-guanine phosphoribosyltransferase, but was normal in the leukocytes of an obligate heterozygote for this enzyme abnormality. The results domonstrate in peripheral human leukocytes the presence of the complete pathway of de novo synthesis of purine nucleotides and the manifestation in these cells of the biochemical consequences of hypoxanthine-guanine phosphoribosyltransferase deficiency, i.e., increased availability of PRPP and acceleration of purine synthesis de novo. The results indicate the usefulness of leukocytes as a model tissue for the study of purine metabolism in man.

Full text

PDF
289

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagnara A. S., Brox L. W., Henderson J. F. Kinetics of amidophosphoribosyltransferase in intact tumor cells. Biochim Biophys Acta. 1974 May 20;350(1):171–182. doi: 10.1016/0005-2744(74)90215-0. [DOI] [PubMed] [Google Scholar]
  2. Bagnara A. S., Letter A. A., Henderson J. F. Multiple mechanisms of regulation of purine biosynthesis de novo in intact tumor cells. Biochim Biophys Acta. 1974 Dec 20;374(3):259–270. doi: 10.1016/0005-2787(74)90247-0. [DOI] [PubMed] [Google Scholar]
  3. Boer P., Lipstein B., De Vries A., Sperling O. The effect of ribose 5-phosphate and 5-phosphoribosyl-1-pyrophosphate availability on de novo synthesis of purine nucleotides in rat liver slices. Biochim Biophys Acta. 1976 Apr 15;432(1):10–17. doi: 10.1016/0005-2787(76)90036-8. [DOI] [PubMed] [Google Scholar]
  4. Boer P., Sperling O., De Vries A. Electrophoretic characterization of human phosphoribosylpyrophosphate synthetase. Biochem Med. 1974 Jun;10(2):175–179. doi: 10.1016/0006-2944(74)90020-9. [DOI] [PubMed] [Google Scholar]
  5. Dancis J., Berman P. H., Jansen V., Balis M. E. Absence of mosaicism in the lymphocyte in X-linked congenital hyperuricosuria. Life Sci. 1968 Jun 15;7(12):587–591. doi: 10.1016/0024-3205(68)90079-9. [DOI] [PubMed] [Google Scholar]
  6. Diamond H. S., Friedland M., Halberstam D., Kaplan D. Glycine-C-14 incorporation into nucleic acid purine by leucocytes obtained from normal and gouty subjects. Ann Rheum Dis. 1969 May;28(3):275–280. doi: 10.1136/ard.28.3.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fox I. H., Kelley W. N. Human phosphoribosylpyrophosphate synthetase. Distribution, purification, and properties. J Biol Chem. 1971 Sep 25;246(18):5739–5748. [PubMed] [Google Scholar]
  8. Fox I. H., Kelley W. N. Observations of altered intracellular phosphoribosylpyrophosphate (PP-ribose-P) in human disease. Adv Exp Med Biol. 1974;41:471–478. doi: 10.1007/978-1-4757-1433-3_12. [DOI] [PubMed] [Google Scholar]
  9. Green C. D., Martin D. W., Jr Characterization of a feedback-resistant phosphoribosylpyrophosphate synthetase from cultured, mutagenized hepatoma cells that overproduce purines. Proc Natl Acad Sci U S A. 1973 Dec;70(12):3698–3702. doi: 10.1073/pnas.70.12.3698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hershko A., Razin A., Mager J. Regulation of the synthesis of 5-phosphoribosyl-I-pyrophosphate in intact red blood cells and in cell-free preparations. Biochim Biophys Acta. 1969 Jun 17;184(1):64–76. doi: 10.1016/0304-4165(69)90099-3. [DOI] [PubMed] [Google Scholar]
  11. Holmes E. W., McDonald J. A., McCord J. M., Wyngaarden J. B., Kelley W. N. Human glutamine phosphoribosylpyrophosphate amidotransferase. Kinetic and regulatory properties. J Biol Chem. 1973 Jan 10;248(1):144–150. [PubMed] [Google Scholar]
  12. Kelley W. N. Effects of drugs on uric acid in man. Annu Rev Pharmacol. 1975;15:327–350. doi: 10.1146/annurev.pa.15.040175.001551. [DOI] [PubMed] [Google Scholar]
  13. Kelley W. N., Fox I. H., Wyngaarden J. B. Regulation of purine biosynthesis in cultured human cells. I. Effects of orotic acid. Biochim Biophys Acta. 1970 Sep 22;215(3):512–516. doi: 10.1016/0304-4165(70)90101-7. [DOI] [PubMed] [Google Scholar]
  14. Kelley W. N. Hypoxanthine-guanine phosphoribosyltransferase deficiency in the Lesch-Nyhan syndrome and gout. Fed Proc. 1968 Jul-Aug;27(4):1047–1052. [PubMed] [Google Scholar]
  15. LEVENBERG B., MELNICK I., BUCHANAN J. M. Biosynthesis of the purines. XV. The effect of aza-L-serine and 6-diazo-5-oxo-L-norleucine on inosinic acid biosynthesis de novo. J Biol Chem. 1957 Mar;225(1):163–176. [PubMed] [Google Scholar]
  16. LOWY B. A., WILLIAMS M. K., LONDON I. M. Enzymatic deficiencies of purine nucleotide synthesis in the human erythrocyte. J Biol Chem. 1962 May;237:1622–1625. [PubMed] [Google Scholar]
  17. Martin D. W., Jr, Owen N. T. Repression and derepression of purine biosynthesis in mammalian hepatoma cells in culture. J Biol Chem. 1972 Sep 10;247(17):5477–5485. [PubMed] [Google Scholar]
  18. Rajalakshmi S., Handschumacher R. E. Control of purine biosynthesis de novo by orotic acid in vivo and in vitro. Biochim Biophys Acta. 1968 Feb 26;155(2):317–325. doi: 10.1016/0005-2787(68)90176-7. [DOI] [PubMed] [Google Scholar]
  19. Rosenbloom F. M., Henderson J. F., Caldwell I. C., Kelley W. N., Seegmiller J. E. Biochemical bases of accelerated purine biosynthesis de novo in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem. 1968 Mar 25;243(6):1166–1173. [PubMed] [Google Scholar]
  20. SCOTT J. L. Human leukocyte metabolism in vitro. I. Incorporation of adenine-8-C-14 and formate-C-14 into the nucleic acids of leukemic leukocytes. J Clin Invest. 1962 Jan;41:67–79. doi: 10.1172/JCI104468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sperling O., Boer P., Persky-Brosh S., Kanarek E., De Vries A. Altered kinetic property of erythrocyte phosphoribosylpsyrophosphate synthetase in excessive purine production. Rev Eur Etud Clin Biol. 1972 Aug-Sep;17(7):703–706. [PubMed] [Google Scholar]
  22. Sperling O., Eilam G., Sara-Persky-Brosh, De Vries A. Accelerated erythrocyte 5-phosphoribosyl-1-pyrophosphate synthesis. A familial abnormality associated with excessive uric acid production and gout. Biochem Med. 1972 Aug;6(4):310–316. doi: 10.1016/0006-2944(72)90017-8. [DOI] [PubMed] [Google Scholar]
  23. Sperling O., Eilam G., Schmidt R., Mundel G., De Vries A. Purine base incorporation into erythrocyte nucleotides in hypoxanthine-guanine phosphoribosyltransferase deficiency. Biochem Med. 1971 Apr;5(2):173–176. doi: 10.1016/0006-2944(71)90085-8. [DOI] [PubMed] [Google Scholar]
  24. Sperling O., Frank M., Ophir R., Liberman U. A., Adam A., de Vries A. Partial deficiency of hypoxanthine-guanine phosphoribosyltransferase associated with gout and uric acid lithiasis. Rev Eur Etud Clin Biol. 1970 Nov;15(9):942–947. [PubMed] [Google Scholar]
  25. Wood A. W., Seegmiller J. E. Properties of 5-phosphoribosyl-1-pyrophosphate amidotransferase from human lymphoblasts. J Biol Chem. 1973 Jan 10;248(1):138–143. [PubMed] [Google Scholar]
  26. Zoref E., De Vries A., Sperling O. Mutant feedback-resistant phosphoribosylpyrophosphate synthetase associated with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts. J Clin Invest. 1975 Nov;56(5):1093–1099. doi: 10.1172/JCI108183. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES